FDA Staff Review Says Data For Co's Duchenne Cell Therapy Does Not Provide Substantial Evidence Of Effectiveness
https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated
The FDA's doctors looked at a company's new cell therapy medicine for a serious muscle disease and said the test results don't show it really works. When regulators doubt a medicine works, the company faces a tough road to selling it, so paying attention to what happens next matters.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.